Subscribe to RSS
DOI: 10.1055/s-2004-828675
Overview of Treatment of Hepatitis B: Key Approaches and Clinical Challenges
Publication History
Publication Date:
11 June 2004 (online)
![](https://www.thieme-connect.de/media/sld/2004S1/lookinside/thumbnails/10.1055-s-2004-828675-1.jpg)
The development of nucleoside analogues has been a major advance in the treatment of hepatitis B; however, prolonged monotherapy is associated with drug resistance. Currently, no data in humans indicate that a combination of nucleoside analogues leads to enhanced efficacy. New nucleoside analogues with greater inhibitory effects on hepatitis B virus (HBV) replication being developed could prove to be more effective or less likely to be associated with viral resistance. Interferon still has a role to play in the management of chronic HBV infection. Recent data indicate that the response to interferon may be determined in part by differences in genotype. From a theoretical perspective, a combination of pegylated interferon with one or more nucleosides could induce a higher rate of virological response. Additional studies are needed to further address these issues.
KEYWORDS
Hepatitis B - nucleoside analogues - interferon - antiviral therapy
REFERENCES
- 1 Perrillo R P. Hepatitis B: treatment strategies for currently available drugs. Curr. Hep. Reports. 2003; 2 63-70
- 2 Liaw Y F, Leung N, Guan R, Lau G KK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol. 2003; 18 239-245
- 3 Lok A SF, McMahon B J. AASLD practice guidelines. Chronic hepatitis B. Hepatology. 2001; 34 1225-1241
- 4 EASL International Consensus Conference on Hepatitis B . 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003; 38 533-540 , (review)
- 5 Perrillo R, Schiff E, Yoshida E et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000; 32 129-134
- 6 Chang T-T, Hadziyannis S, Cianciara J et al.. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology. 2002; 36 300A , (Abst)
- 7 van Bommel F, Wunsche T, Schurmann D et al.. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology. 2003; 38 275A , (Abst)
- 8 Perrillo R, Tamburro C, Regenstein F et al.. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995; 109 908-916
- 9 Nair S, Perrillo R P. Hepatitis B and D. In: Zakim D, Boyer T Hepatology: A Textbook of Liver Disease. Philadelphia; Saunders 2003: 959-1016
- 10 Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001; 120 1009-1022
- 11 Honkoop P, de Man R A, Niesters H G et al.. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32 635-639
- 12 Wright T L. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis. 2004; 24(suppl 1) 31-36
- 13 Locarnini S A. Molecular virology of hepatitis B. Semin Liver Dis. 2004; 24(suppl 1) 3-10
- 14 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124 105-117
- 15 Mutimer D, Pillay D, Shields P et al.. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut. 2000; 46 107-113
- 16 Perrillo R, Hann H W, Mutimer D et al.. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis virus. Gastroenterology. 2004; 126 81-90
- 17 Peters M G, Hann H W, Heathcote E et al.. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant hepatitis B. Gastroenterology. 2004; 126 91-101
- 18 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125 292-297
- 19 Colonno R J, Weinheimer S, Rose R et al.. Emerging amino acid substitutions in lamivudine-resistant HBV that result in reduced susceptibility to entecavir. Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, 2003 Chicago, IL;
- 20 Lai C-L, Leung N WY, Teo E-T et al.. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B. Hepatology. 2003; 38 262A , (Abst)
- 21 Sung J JY, Lai J Y, Zeuzem S et al.. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naïve patients with chronic hepatitis B: week 52 analysis. J Hepatol. 2003; 38 25-26 , (Abst)
- 22 Wong D K, Cheung A M, O'Rourke K et al.. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119 312-323
- 23 Nair S, Perrillo R. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?. Hepatology. 2001; 34 1021-1026
- 24 Cooksley W GE, Piratvisuth T, Lee S-D et al.. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10 298-305
- 25 Cooksley W G. Treatment with interferons in patients with hepatitis B. Semin Liver Dis. 2004; 24(suppl 1) 45-54
- 26 Marcellin P, Lau G KK, Bonino F et al.. A phase II, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2° (40KD) (Pegasys®) alone or in combination with lamivudine vs lamivudine in 537 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. Hepatology. 2003; 38 724A , (Abst)
- 27 Hansen H LA, Senturk H, Zeuzem S et al.. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg positive chronic hepatitis B: a randomized controlled trial in 307 patients. Presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases October 28, 2003 Boston, MA;
- 28 Westland C, Delaney IV W, Yang H et al.. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003; 125 107-116
- 29 Kao J H, Wu N H, Chen P J et al.. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000; 33 998-1002
- 30 Chu C-J, Keeffe E B, Han S-H et al.. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003; 125 444-451
- 31 Korba B E, Cote P, Hornbuckle W et al.. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferono against WHV replication in chronic carrier woodchucks. Antivir Ther. 2000; 5 95-104
- 32 Schalm S W, Heathcote J, Cianciara J et al.. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut. 2000; 46 562-568
- 33 Santantonio T, Niro G A, Sinisi E et al.. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol. 2003; 36 799-804
- 34 Samuel D. Management of Hepatitis B in liver transplantation patients. Semin Liver Dis. 2004; 24(suppl 1) 55-62
Robert P PerrilloM.D.
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation
1514 Jefferson Highway
New Orleans, LA 70121
Email: rperrillo@ochsner.org